In September 2023, the FDA added BPC-157 to its Category 2 list of bulk drug substances under its Interim Policy on Compounding, meaning 503A compounding pharmacies and 503B outsourcing facilities are barred from using it in compounded preparations
It's clearly a first step in the right direction. Braddocks opinion is grounded in regulatory process since being on the Bulks List means a drug must have traceable ingredients and undergo testing for contamination
In preclinical studies, BPC-157 is typically dosed at 200500 mcg/kg, TB-500 at 210 mg/kg, and GHK-Cu at 13 mg/kg, administered via subcutaneous injection, intravenous infusion, or direct tissue injection depending on study design
We ensure that you receive comprehensive care and monitoring during the procedure
They rarely describe failure states: persistent cloudiness from aggregated peptide, gel-like consistency from incomplete dissolution of a large pellet, or a precipitate forming hours after initial clarity due to slow aggregation
Int J Pharm Pharm Sci 7(3):198202 Kowsalya S, Sudhaparimala S (2025) Nanoscale hydroxyapatite from marine and synthetic calcium sourcesfor efficient removal of p -chlorophenol